ALNY — Alnylam Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $42.09bn
- $41.88bn
- $3.71bn
Annual income statement for Alnylam Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 844 | 1,037 | 1,828 | 2,248 | 3,714 |
| Cost of Revenue | |||||
| Gross Profit | 704 | 869 | 1,518 | 1,925 | 3,032 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,553 | 1,899 | 2,110 | 2,425 | 3,255 |
| Operating Profit | -709 | -862 | -282 | -177 | 459 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -852 | -1,127 | -434 | -377 | 323 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -853 | -1,131 | -440 | -278 | 314 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -853 | -1,131 | -440 | -278 | 314 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -853 | -1,131 | -440 | -278 | 314 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.2 | -8.89 | -3.52 | -2.18 | 2.64 |